CD8A and neoplasm: Immune checkpoint inhibitors are believed to reestablish tumor immune surveillance by acting on the programmed cell death-1 receptor (PD1) on exhausted CD8+ T cells, or the programmed cell death 1 ligand 1 (PD-L1) on tumor cells (18, 21–23).